Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Waldenstrom Macroglobulinemia
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Lymphoplasmacytic Lymphoma (64
)
Lymphoplasmacytic Lymphoma (64
)
›
Associations
(62)
News
Trials
Search handles
@AaronGoodman33
@HadidiSamer
@MinnemaMonique
@Myeloma_Doc
@SLentzsch
@docbraunstein
@mtmdphd
@syed_abutalibmd
Search handles
@AaronGoodman33
@HadidiSamer
@MinnemaMonique
@Myeloma_Doc
@SLentzsch
@docbraunstein
@mtmdphd
@syed_abutalibmd
Filter by
Latest
9ms
@JudithTrotman1 @MinnemaMonique @c_thieblemont #KarimaAmaador @lymphomaOz #lymphoma #MZL #WM #WaldenströmsMacroglobulinemia (@WomenInLymphoma)
9 months ago
10ms
The CD20-targeted CAR T-cell therapy MB-106 led to responses and was well tolerated in patients with Waldenström macroglobulinemia who were refractory to a BTK inhibitor. @mshadman @fredhutch @EHA_Hematology #EHA2023 #oncology https://t.co/NEbQErcVsD (@OncLive)
10 months ago
Clinical • CAR T-Cell Therapy
10ms
Carlos Fernandez de Larrea (@fdezdelarrea), hematólogo del @hospitalclinic y jefe del grupo sobre Mieloma, amiloidosis, macroglobulinemia y otras gammapatías del @idibaps. Coordinador del ensayo del #MielomaMúltiple. Por ✍ @carmenfefe: ➡️https://t.co/mboz5HJW6M (@diariomedico)
10 months ago
Clinical
10ms
In a single-center phase 1/2 trial, MB-106 produced ongoing responses and a favorable safety profile in patients with Waldenström macroglobulinemia who were refractory to a BTK inhibitor. @mshadman @fredhutch @EHA_Hematology #EHA2023 #oncology https://t.co/ViIyzyXWFW (@OncLive)
10 months ago
Clinical
10ms
My mum had cold agglutinin disease as a complication of Waldenstrom’s Macroglobulinemia. (@pauliec80859931)
10 months ago
11ms
Wrapped up our second day of interviews here at #EHA2023 with @mshadman (@fredhutch), who spoke on MB-106 in patients with Waldenström's macroglobulinemia & follicular lymphoma, the SEQUOIA trial & more! Check out our coverage here: 👉 https://t.co/2U3kjqJyaP @EHA_Hematology (@VJHemOnc)
11 months ago
Clinical • Interview
11ms
I am #proud to share that our paper on Waldenstrom macroglobulinemia in #latam has been published in #Hematology/Oncology Clinics of North America. Thanks to all the team for the hard work. #LATAM @gelamm_latam @dra_v_hungria @erivaserra @CarlosChiattone 🇨🇴🇧🇷🇺🇾 #lymphoma (@HumbertoMar_Cor)
11 months ago
11ms
📣Our latest @TheIACH Webinar: Management of Waldenstrom Macroglobulinemia: an update Now available on-demand! 📽️View the full webinar for FREE ⬇️⬇️⬇️ https://t.co/HHXnQkRGVP @MinnemaMonique @Mohty_EBMT (@TheIACH)
11 months ago
11ms
📣Join @MinnemaMonique TODAY for @TheIACH Webinar: Management of Waldenstrom Macroglobulinemia: an update FREE registration👉https://t.co/EoWxOb7MpB @Mohty_EBMT (@TheIACH)
11 months ago
11ms
📣Join us NOW! ⬇️ https://t.co/rF7AyMtvBh Management of Waldenstrom Macroglobulinemia: an update FREE registration!✍️ @MinnemaMonique @Mohty_EBMT (@TheIACH)
11 months ago
11ms
📣Join @MinnemaMonique TOMORROW for @TheIACH Webinar: Management of Waldenstrom Macroglobulinemia: an update with FREE registration👉 https://t.co/EoWxOb7eA3 @Mohty_EBMT (@TheIACH)
11 months ago
11ms
👉🏽💻@MinnemaMonique #WM #WaldenstromMacroglobulinemia update webinar - This WED MAY 24 Free registration 👉🏽 https://t.co/tfNFyCoq2a (@WomenInLymphoma)
11 months ago
11ms
📣Join us for this upcoming @TheIACH Webinar: Management of Waldenstrom Macroglobulinemia: an update with @MinnemaMonique FREE registration⬇️ https://t.co/EoWxOb7eA3 @Mohty_EBMT (@TheIACH)
11 months ago
11ms
Please join me for live Q&A this Wednesday 24th of May after the @TheIACH Webinar: Management of Waldenstrom Macroglobulinemia FREE registration⬇️ https://t.co/QAedxKKfap @Mohty_EBMT (@MinnemaMonique)
11 months ago
12ms
Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia | Journal of Clinical Oncology https://t.co/tPDTO24jzv (@syed_abutalibmd)
12 months ago
Clinical
|
Rituxan (rituximab) • bortezomib • cyclophosphamide
over1year
Good teaching case from @BloodJournal Images in #Hematology that (1) not all M-spikes are myeloma, (2) not all lymphoplasmacytic lymphomas are IgM isotype, and (3) remember to request MYD88 and CXCR4 mutations in this setting. #mmsm https://t.co/OpVazjbeNA (@docbraunstein)
over 1 year ago
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4)
|
CXCR4 mutation • MYD88 mutation + CXCR4 mutation
over1year
No difference in 4-year PFS between MYD88 mutant vs wild-type with frontline BR (benda/ritux) in Waldenstrom Macroglobulinemia #waldenstroms #wm #hematology #mayoclinic #myd88 @MyelomaDrKapoor (@NateDahlPharmD)
over 1 year ago
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor)
|
MYD88 mutation
almost2years
The CD19 #antigen has gotten a lot of attention from FDA-approved #CARTcelltherapies, but Mustang Bio is focused on a CD20-targeted #CARTcelltherapy for #nonHodgkinlymphoma, #chroniclymphocyticleukemia, & #Waldenstrommacroglobulinemia. https://t.co/V7GaF1ZXJv #ASGCT22 #ASGCT2022 (@Slabodkin)
almost 2 years ago
FDA event • CAR T-Cell Therapy
|
CD19 (CD19 Molecule)
2years
#Myeloma Paper of the Day: CD19-directed chimeric antigen receptor T cell therapy in #Waldenström macroglobulinemia shows both in vitro & in vivo preclinical efficacy and activity in 3 patients, whose remission durations were 3-26 months: patients):https://t.co/Q8eIqzL1Ux. (@Myeloma_Doc)
2 years ago
CAR T-Cell Therapy
|
CD19 (CD19 Molecule)
2years
New #JITC short report: CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience https://t.co/gw0qB7kAtg @LiaPalomba @davidquallsmd @ESmithMDPhD (@jitcancer)
2 years ago
CAR T-Cell Therapy
|
CD19 (CD19 Molecule)
2years
B-cell Lymphoma Flow Cytometry Simplified B-cell = CD19+ CD5+/CD10- = CLL (CD23+) Mantle cell (CD23-) CD10+ = Follicular Burkitt DLBCL (GCB subtype) CD5-/CD10- = Marginal zone Lymphoplasmacytic/Waldenstrom's macroglobulinemia Hairy cell leukemia DLBCL (non-GCB) (@AaronGoodman33)
2 years ago
CD19 (CD19 Molecule) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase) • FCER2 (Fc Fragment Of IgE Receptor II)
over2years
Our latest study in Waldenström's Macroglobulinemia is out in @ScienceAdvances We found mutated MYD88 in normal B cells. This challenges our understanding of lymphomagenesis (mutated MYD88 ≠ lymphoma) and urges alternative methods of disease monitoring https://t.co/xFxOsZjl31 (@BrunoPaiva_UNAV)
over 2 years ago
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor)
|
MYD88 mutation
over2years
Heme Board Review - Bing Neel Syndrome! Rare manifestation of Waldenström’s macroglobulinemia/LPL Infiltration of the CNS by lymphoplasmacytic cells Usually at disease relapse but can occur at presentation CSF cytology = flow CD5-/CD10- MYD88 L265P+ Rx = HDMTX, ibrutinib (@AaronGoodman33)
over 2 years ago
Review
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase)
|
MYD88 L265P
|
Imbruvica (ibrutinib)
over2years
Venetoclax in Previously Treated Waldenström Macroglobulinemia @JCO_ASCO 👉🏻 ORR84%👉🏻CXCR4 mutations did not affect treatment response or progression-free survival #mmsm | Journal of Clinical Oncology https://t.co/jDzNGbOCPS (@SLentzsch)
over 2 years ago
Clinical
|
CXCR4 (Chemokine (C-X-C motif) receptor 4)
|
CXCR4 mutation
|
Venclexta (venetoclax)
over2years
Morning Board Review - Bing Neel Syndrome! Rare manifestation of Waldenström’s macroglobulinemia/LPL Infiltration of the CNS by lymphoplasmacytic cells Usually at disease relapse but can occur at presentation CSF cytology = flow CD5-/CD10- MYD88 L265P+ Rx = HDMTX, ibrutinib (@AaronGoodman33)
over 2 years ago
Review
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase)
|
MYD88 L265P
|
Imbruvica (ibrutinib)
over2years
Waldenstorm macroglobulinemia #mmsm ➡️Lymphoid (+ve B cell markers, CD20)/plasmacytoid (+ve CD138)👇 ➡️Mutations: 🩸MYD88:L265P,most common, helps in diff from MM, mutated=good prog 🩸CXCR4:less common, mutated=worse prog ➡️excellent review @MorieGertz: https://t.co/UmDrQj69wt (@HadidiSamer)
over 2 years ago
Review
|
CD20 (Membrane Spanning 4-Domains A1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • SDC1 (Syndecan 1)
|
MYD88 L265P
over2years
Recently,[Dale. Blood. 2020] showed the CXCR4 inhibitor mavorixafor can increase circulating PMNs and decrease infections in WHIM patients. Interestingly, the same CXCR4 mutation in WHIM is seen in Waldenstrom macroglobulinemia and is associated with worse responses to ibrutinib (@AaronGoodman33)
over 2 years ago
Clinical
|
CXCR4 (Chemokine (C-X-C motif) receptor 4)
|
CXCR4 mutation
|
Imbruvica (ibrutinib) • mavorixafor (X4P-001)
over2years
Anyone know of #CART trials for Waldenstrom Macroglobulinemia ongoing ? (Seen reports of WM to rx DLBCL getting cd19 car) @MediHumdani @DrMiguelPerales @drjgauthier @bhemato @kenderian_ss (@kansagraMD)
over 2 years ago
CD19 (CD19 Molecule)
over3years
Interesting. Would treat as MM. 2019 - Simultaneous Presentation of Waldenström's Macroglobulinemia and MYD88 Gene Mutation with Multiple Myeloma https://t.co/imK0mvoxlB #mmsm #wmsm (@mtmdphd)
over 3 years ago
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login